Acute myeloid leukemia (AML) is heterogeneous in clinical features and molecular pathogenesis. Cooperating alterations of several genes, including oncogenes or tumor suppressor genes, lead to AML development. 1 AML leukemogenesis is thought to require at least two different types of genetic change: class I mutations, which confer a proliferative or survival advantage; and class II mutations, which block myeloid differentiation and provide self-renewability. 1 In hematological malignancies with 11p15 translocations, the nucleoporin (NUP) 98 gene is reportedly fused to various partner genes, often including homeobox genes, such as HOXA9, A11, A13, C11, C13, D11, D13 and PMX1.
2 With respect to the oncogenic mechanism of NUP98-HOX fusion proteins, a previous study using a murine bone marrow transplantation assay revealed that NUP98-HOXA9, -HOXD13 and -PMX1 fusion proteins induce myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN), which progress to AML. 2 This latency period indicates that additional genetic events might be required for leukemic transformation. Therefore, we examined somatic mutations of the FLT3, KIT, WT1, RUNX1, CEBPA, NPM1, NRAS, KRAS and MLL genes, which are prevalent in AML, in leukemia patients with NUP98 fusion genes. This study was approved by local ethical committee.
Sixteen patients with chromosomal 11p15 translocations included nine with NUP98-HOXA9, two with NUP98-HOXA13, two with NUP98-HOXA11 and one each with NUP98-HOXC11, NUP98-HOXD11, NUP98-HOXD13 or NUP98-NSD3 (Table 1) . The partner gene fused to NUP98 could not be detected in one patient with t(4;11)(q21;p15); however, fluorescent in situ hybridization analysis using a probe containing NUP98 showed split signals (data not shown). No patients had any additional chromosomal abnormality except for chromosomal 11p15 translocations (Supplementary data). Two patients with t(7;11)(p15;p15) had double NUP98 fusion transcripts: patient (PN) 13 had simultaneous NUP98-HOXA9 and NUP98-HOXA13 fusions, and PN14 had simultaneous NUP98-HOXA9 and NUP98-HOXA11 fusions. In all, 15 of the 16 patients with NUP98-related hematological malignancies were diagnosed as having myeloid malignancies, and the other patient (PN16) were initially diagnosed as having T-cell nonHodgkin's lymphoma with t(4;11)(q21;p15), and transformed into acute myelomonocytic leukemia with the same t(4;11) (lineage switch). Patients with myeloid malignancies consisted of 10 patients with AML, 2 patients with MDS and 3 patients with MPN.
We examined the internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations of the FLT3 gene in 16 patients, and detected ITDs in nine (56.3%) patients, and TKD mutations in none (Table 1, Figure 1a ). The incidence of FLT3-ITD in our study was much higher than that in an AML cohort reported previously (12-35%).
1 A high frequency of FLT3-ITD was previously reported in 30-35% of AML patients with either normal karyotype or with t(15;17)(q21;q11) resulting in PML-RARA, and in 70% of AML patients with t(6;9)(p23;q34) resulting in DEK-CAN/NUP214.
1 Interestingly, both NUP98 and NUP214 encode a part of the nucleoporin complex. The general activation effects on reporters of the DEK-CAN/NUP214 fusion protein are specific for myeloid cells. 3 Moreover, in murine bone marrow transplantation assays, NUP98-related fusion proteins such as NUP98-HOXA9, -HOXD13 and -PMX1 induced MDS or MPN, which progressed to AML. 2 These results demonstrate that the nucleoporin-related proteins share a common ability for myeloid differentiation. Furthermore, the very tight correlation between nucleoporin-related fusion genes and FLT3-ITD suggest that FLT3-ITD may contribute to the myeloid leukemogenesis involved in nucleoporin-related fusions.
We further examined mutations of the KIT, WT1, AML1, CEBPA, NPM1, NRAS, KRAS and MLL genes, 4 which are prevalent in AML. KIT, NRAS and KRAS mutations were found in four (25.0%), three (18.8%) and two (12.5%) patients, respectively (Table 1, Figure 1b) . WT1 aberrations were found in eight patients (50.0%; Table 1, Figure 1c) . No mutations were found in the other four genes (RUNX1, CEBPA, NPM1 and MLL). The mutations in KIT were all missense mutations including Val399Ile, Met541Leu and Asp816Val, and all mutations of NRAS and KRAS were Gly13Asp. All of KIT, NRAS and KRAS mutations were heterozygous. The aberrations in WT1 comprised a frameshift insertion of exon 7 in four patients, missense mutation of exon 9 in one, deletion of exon 5 in one and deletion of the whole cording region in two. Frameshift and missense mutation of WT1 are heterozygous, whereas deletion was homozygous. FLT3-ITD, KIT and RAS mutations reportedly confer cellular proliferative abilities. 1 In our study, 14 patients (88%) had at least one mutation involved in cellular proliferation (FLT3, KIT or RAS). Recently, Chou et al. 5 reported that the NUP98-HOXA9 fusion is strongly associated with KRAS and WT1 mutations. Nras and Kras mutations were frequently found in AML developed in transgenic mice expressing NUP98-HOXD13. 6 These results indicate that NUP98-related leukemias have a high frequency of mutations involved in growth advantage.
Interestingly, five of the six patients with WT1 aberrations had FLT3-ITD, and three of the five patients with both FLT3-ITD and WT1 aberrations had a KIT mutation, although the simultaneous FLT3-ITD and KIT mutations are reportedly very rare 1 . These results suggest that the NUP98-related leukemias share a distinct molecular subgroup in leukemias. In addition, all four patients with KIT mutations had both FLT3-ITD (P ¼ 0.04) and WT1 aberrations (P ¼ 0.03), whereas all five patients with RAS mutations did not have FLT3-ITD. In all, 14 (88%) of the 16 patients had either FLT3-ITD or RAS mutations, but they were mutually exclusive as described in previous papers. 1 These Abbreviations: AML, acute myeloid leukemia; Chemo, chemotherapy; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR, complete remission; del, deletion; F, female; JMML, Juvenile myelomonocystic leukemia; M, male; ND, not determined; Ph-, Philadelphia chromosome; PN, patient number; RA, refractory anemia; RAEB-t, refractory anemia with excess of blasts in transformation; SCT, stem cell transplantation; T-NHL, T-cell non-Hodgkin's lymphoma; WBC, white blood cell; WT, wild type. t(11;12), t(11;12)(p15;q13); t(2;11), t(2;11)(q31;p15); t(4;11), t(4;11)(q21;p15); t(7;11), t(7;11)(p15;p15); t(8;11), t(8;11; p11; p15). Letters to the Editor suggest the distinct molecular basis between NUP98-related leukemias having FLT3-ITD and those having RAS mutations. The relationships between clinical features and gene mutations were described in Table 1 . In our study, male patients were more likely than female patients to have FLT3-ITD (P ¼ 0.01) and patients with FLT3-ITD have leukocytosis (P ¼ 0.08) more than those without FLT3-ITD. Patients with RAS mutations were significantly younger than those without the mutations (median age of 15 vs 56 years; P ¼ 0.04). In total, 9 (64.3%) of the 14 patients who achieved complete remission relapsed, and 9 (60.0%) of the 15 patients whose data were available died, although they were treated by different protocols (Table 1 ). All three patients who had both FLT3-ITD and KIT mutations, and five (83.3%) of the six patients who had both FLT3-ITD and WT1 aberrations, died. Many studies have shown that FLT3-ITD is related to a poor prognosis in AML patients, 1 and that KIT mutations are associated with a worse outcome in CBF-leukemia patients.
1 WT1 mutations are also reported to be a poor prognostic factor in adult AML patients with normal karyotypes. 7 These results suggest that simultaneous occurrence of FLT3-ITD, KIT mutations and WT1 aberrations in NUP98-related leukemia may be associated with poor prognosis.
FLT3-ITD, KIT and RAS mutations lead to constitutive activation of downstream pathway, resulting in acquirement of a proliferative advantage.
1 In a mouse model, FLT3-ITD alone does not induce AML, and RAS mutations can induce myeloid leukemia with distinct leukemogenic strengths and phenotypes. 1 NUP98-related fusions alone require long periods of time to induce AML, although these fusions induce MDS or MPN by impaired myeloid differentiation. 2 Cooperation between BCR-ABL (which enhances proliferation) and NUP98-fusion (which inhibits differentiation) lead to CML blast crisis. 2 Moreover, the WT1 mutations were clustered within the DNA binding domain, and were subsequently considered to impair the ability of DNA to bind to target genes associated with apoptosis, cell cycle or cellular proliferation. 8 These results suggest that a high frequency of cell proliferation gene mutations may contribute to leukemogenesis in NUP98-related leukemia, and that simultaneous occurrence of FLT3-ITD and WT1 aberrations may have an important role in the clinical outcome of NUP98-related leukemia.
